NCT06683040View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Oxacom

Lyophilisate for solution for intravenous administration, 6.3 mg

DRUG

Placebo

0.9% sodium chloride

Trial Locations (1)

121552

RECRUITING

NMCRCardiologyRu, Moscow

All Listed Sponsors
lead

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

OTHER_GOV